AI Article Synopsis

  • * In vitro tests demonstrated that brief HIFU treatment with adequate RB2 concentration can kill over 95% of MDA-MB-231 breast cancer cells, while neither treatment alone had significant effects.
  • * In vivo studies using mice showed that HIFU can cause tumor regression; however, injecting RB2 significantly improved the results, indicating a synergistic effect when both treatments are used together.

Article Abstract

Pulsed high intensity focused ultrasound (HIFU) has been combined with a photo-insensitive Rose Bengal derivative (RB2) to provide a synergistic cytotoxicity requiring the presence of both ultrasonic cavitation and drug. In vitro tests have shown that a short treatment (less than 30 s) of pulsed HIFU with peak negative pressure >7 MPa (~27 W acoustic power at 1.4 MHz) destroys >95% of breast cancer cells MDA-MB-231 in suspension with >10 μM of the compound. Neither the pulsed HIFU nor the RB2 compound was found to have any significant impact on the viability of the cells when used alone. Introducing an antioxidant (N-acetylcysteine) reduced the effectiveness of the treatment. In vivo tests using these same cells growing as a xenograft in nu/nu mice were also done. An ultrasound contrast agent (Optison) and lower frequency (1.0 MHz) was used to help initiate cavitation at the tumor site. We were able to demonstrate tumor regression with cavitation alone, however, addition of RB2 compound injected i.v. yielded a substantial synergistic improvement.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230682PMC
http://dx.doi.org/10.1016/j.jconrel.2011.08.016DOI Listing

Publication Analysis

Top Keywords

rose bengal
8
bengal derivative
8
focused ultrasound
8
pulsed hifu
8
rb2 compound
8
cancer treatment
4
treatment optically
4
optically inert
4
inert rose
4
derivative combined
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!